Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

This is a non randomized, open label, single dose, parallel cohort, multisite study to
investigate the effect of varying degrees of hepatic impairment on the plasma
pharmacokinetics (total and unbound) of PF-05221304 after a single oral dose administered in
the fed state.

Key Exclusion Criteria:

All subjects -

- Adults <18 years of age and >70 years of age

- BMI < 17.5 and > 35.4 kg/m2

- HIV positive

- Conditions that affect drug absorption

- Positive breath alcohol test

Healthy/ those without hepatic impairment -

- Known or suspected hepatic impairment

- Evidence of Hepatitis B or C

- On any chronic medications

Those with varying degrees of hepatic impairment -

- Not meeting Classification A, B, or C of hepatic impairment based on Child-Pugh
Classification

- Evidence of Hepatic carcinoma or hepatorenal syndrome or limited predicted life
expectancy

- Recent GI bleed

- Moderate or severe renal impairment

- Hepatic encephalopathy Grade 3 or higher